CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 15 enrolled
Drug / intervention
brimonidine 0.1% (Alphagan® P)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00457795
NCT00457795Phase 4Completed
CompareCT.gov

24-hour IOP-lowering Effect of Brimonidine 0.1%

Allergan·interventional·Posted Apr 9, 2007·Updated Nov 24, 2011

In Brief

A Phase 4 clinical trial evaluating brimonidine 0.1% (Alphagan® P) for Open-angle Glaucoma and Ocular Hypertension. Completed, enrolled 15 participants across 1 site.

Detailed Summary

This study will evaluate the efficacy and safety of brimonidine 0.1% three-times daily in patients with glaucoma or ocular hypertension

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen-angle Glaucoma, Ocular Hypertension
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 9, 2007
Enrollment StartDec 1, 2006
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 19.2 years ago

Interventions

brimonidine 0.1% (Alphagan® P)drug

Brimonidine 0.1%, 1 drop three-times daily for 4 weeks